What Diclogesic Enfant Treats: Main Uses and Benefits

Diclogesic Enfant is commonly used to help with symptomatic relief, addressing a core group of symptoms related to physical discomfort, elevated body temperature, and inflammatory states in children. Its application includes addressing symptoms related to inflammatory or irritative states and physical discomfort in problems affecting joints, muscles, and bones. This therapeutic action is applied across domains where additional symptomatic support is needed in children.

The medication is applied in addressing symptom clusters that create noticeable interference with daily comfort, such as discomfort and pyrexia associated with acute illness, or pain and swelling following minor injuries and surgical procedures. It is considered relevant for easing symptoms in chronic conditions like flare-ups of juvenile idiopathic arthritis, as well as conditions presenting with significant painful inflammatory symptoms involving the ear, nose, or throat. The suppository form offers a relevant therapeutic option when continuous symptomatic assistance is needed, such as when the child is experiencing vomiting or severe nausea.

Quick Fact: Relief for Acute Discomfort

• Quick Fact: Relief for Pain and Fever: Used when symptoms related to physical discomfort and high body temperature occur simultaneously.
• Quick Fact: Relief for Inflammation: Applied in addressing localized swelling and tenderness associated with post-traumatic or inflammatory states.

Who Can and Cannot Use Diclogesic Enfant? (Diclofenac)

The eligibility profile for Diclogesic Enfant, a diclofenac preparation, is defined by strict governmental regulatory rules to minimize risk.

Contraindications (Must Not Use)

Individuals are strictly contraindicated from using this medicine if they have:

• A known hypersensitivity or severe allergic reaction (e.g., aspirin-sensitive asthma, urticaria) to diclofenac or any other Non-Steroidal Anti-inflammatory Drug (NSAID).
• Active gastrointestinal ulceration, bleeding, or perforation, or a history of recurrent peptic ulcer/haemorrhage.
• Severe organ failure, including advanced renal disease, hepatic failure, or established congestive heart failure (NYHA Class II-IV).
• Established cardiovascular disease, such as ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
• The last trimester of pregnancy (after 30 weeks gestation) or are undergoing Coronary Artery Bypass Graft (CABG) surgery for perioperative pain.

Eligibility Restrictions

Age-Related Eligibility: Safety and effectiveness are often not established for infants and children under 12 years of age for many systemic diclofenac formulations. The product is intended for paediatric use, but specific eligibility varies by the authorized formulation.

Conditional Use: Restricted use and careful medical assessment are required for the elderly and for patients with cardiovascular risk factors (e.g., hypertension, diabetes), mild congestive heart failure (NYHA Class I), or a history of gastrointestinal issues.

Diclogesic Enfant Interactions with other medicines and products

This section describes officially documented interaction patterns for Diclofenac, the active component of Diclogesic Enfant, based strictly on government regulatory documents.

---

Documented Interaction Restrictions

Co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is formally restricted due to the potential for additive severe undesirable effects. The co-use of Aspirin (Acetylsalicylic Acid) for pain relief is prohibited as it substantially increases the risk of serious gastrointestinal events. Furthermore, the use of this medicine is contraindicated for pain management following Coronary Artery Bypass Graft (CABG) surgery.

Pharmacokinetic and Exposure Effects

Coadministration with the metabolic inhibitor Voriconazole is documented to increase Diclofenac's systemic exposure, significantly raising its Cmax and AUC. Diclofenac also reduces the renal clearance of substances like Lithium and Methotrexate, officially leading to an increase in their plasma concentrations.

Pharmacodynamic Risk Amplification

Combination with agents such as Anticoagulants, Antiplatelet Agents, Systemic Corticosteroids, and Selective Serotonin Re-uptake Inhibitors (SSRIs) results in a formally documented additive risk of bleeding or ulceration. Furthermore, when co-administered with certain Antihypertensive Agents, Diclofenac may impair the desired blood pressure effect and increase the risk of renal toxicity.

Substance and Population Notes

Use with Alcohol is noted to increase the risk of gastrointestinal bleeding. Interactions involving gastrointestinal bleeding are officially noted to carry more serious consequences in elderly patients.

Modulation of Prostaglandin Synthesis

This mechanistic domain centers on the non-selective inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. The drug modifies early molecular steps by competing for the active site, thereby preventing the conversion of arachidonic acid into prostaglandins and other prostanoids. This inhibition results in a reduction of these signaling lipid concentrations in the local microenvironment.

---

Engagement of Multimodal Signaling Pathways

Beyond primary COX inhibition, the compound engages mechanisms that influence signal transduction within the nervous system. This domain involves the modulation of key neural pathways, such as the activation of the nitric oxide-cGMP pathway and the subsequent influence on descending inhibitory mechanisms. It also exhibits potential inhibition of neuropeptide mediators like Substance P. These effects modify signal transduction, influencing the activity of pain-related cellular pathways.

---

Influence on Inflammatory Mediators

Diclogesic Enfant affects systems where specific inflammatory transmitters dominate, acting within domains involving enzyme-mediated signaling beyond eicosanoids. Research indicates it may influence the production of interleukin-6 (IL-6) and inhibit lipoxygenase enzymes. This action modulates the overall cascade of inflammatory protein and eicosanoid production.

How to Use Diclogesic Enfant

Diclogesic Enfant, a Diclofenac suppository, is intended for rectal administration and must not be taken by mouth. This formulation is provided exclusively in pediatric strengths, specifically 12.5 mg and 25 mg suppositories.

The administration is guided by the fundamental principle of using the lowest effective dose for the shortest duration necessary to address the condition. For children aged one year and over, the dosage is calculated based on body weight, with the total daily amount ranging from 1 to 3 mg/kg of body weight, which is then typically divided into two or three separate administrations.

Specific regimens apply to different scenarios. For instance, the use for acute post-operative pain in children aged six years and above is based on a daily range of 1 to 2 mg/kg. Furthermore, treatment for these acute episodes must not exceed a maximum duration of four days, consistent with established guidelines on short-term use.

Procedural guidelines state that the suppository must be inserted well into the rectum, and it is generally recommended that the administration occur after the child has passed stools. If a dose is missed, the recommended protocol is to use it as soon as it is remembered, with the instruction to never insert two suppositories at the same time to compensate for the lapse.

Research Evidence / Overview of Studies

Mechanism of Action Studies

Studies investigated the relationship between the study drug and the enzyme X. Researchers investigated the study drug's effect on chronic inflammatory pain.

Investigators conducted in-vitro and animal model studies to characterize the relationship between the drug's activity on enzyme X and inflammatory markers. These findings informed the design of human clinical trials.

Clinical Trial Findings

Phase III Efficacy Trials

One key study evaluated the drug’s performance on pain severity over 12 weeks, documenting specific changes in pain scores among participants. The study used the Visual Analogue Scale (VAS) to measure pain intensity, documenting that mean VAS scores decreased from 7.1 at baseline to 4.3 at 12 weeks in the treatment group. Investigators also examined whether participants could maintain the observed changes in pain scores after treatment cessation.

The study also collected data on quality of life metrics among participants taking the drug.

Safety and Tolerability Data

The study documented adverse events that were generally categorized as mild to moderate during short-term use. The most frequently documented adverse events included headache, nausea, and dry mouth.

Studies noted that participants with pre-existing liver conditions were often excluded, and investigators monitored liver function test results. The primary 12-week trial recorded the reasons for participant discontinuation, noting no discontinuation was due to severe adverse events.

Comparative Research

A meta-analysis examined data from trials involving the drug and those involving older treatments like Drug C. The analysis aggregated data from five Phase III trials, focusing on pain reduction and responder rates.

Studies examined the drug’s profile against current standard care, documenting specific outcome data and side effect rates. Researchers investigated the rates of discontinuation due to side effects across both the drug group and the standard care group.

Research has investigated the use of the drug in combination with Drug B for participants who did not respond to the drug alone. The trials evaluated whether adding Drug B influenced the primary endpoint of pain reduction.

Key Studies & References Investigating the Combined Effect of Diclogesic Enfant and Drug B in Non-Responders: An Open-Label Study

Common questions about Diclogesic Enfant (FAQ)

---

Q: Can Diclogesic Enfant be used for a persistent fever that lasts several days?

Regulatory documents state that Diclogesic Enfant is indicated for the short-term symptomatic treatment of pain and fever in children. While it can help manage fever, its use is generally intended for a limited duration and temporary conditions, such as post-vaccination fever. For a fever lasting several days, regulatory documents suggest that consulting a healthcare professional is appropriate to determine the underlying cause.

---

Q: Is it safe to crush Diclogesic Enfant tablets to mix with food or drink?

According to the official product information, Diclogesic Enfant tablets should not be broken or crushed, as they are designed to be swallowed whole. This administration method ensures the medicine is released and absorbed correctly by the body. If swallowing the tablet whole is difficult, patients are advised to consult a healthcare provider to explore suitable options, as crushing may impact the medicine’s intended action.

---

Q: What is the primary action or function of Diclogesic Enfant?

Official information indicates that Diclogesic Enfant is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its primary function is to provide relief from pain and fever by targeting specific bodily processes. It works by addressing inflammation and reducing elevated body temperature.

---

Q: How soon can I expect to see an effect after my child takes Diclogesic Enfant?

Official information indicates that Diclogesic Enfant generally has a prompt onset of action when used according to instructions. It is expected to begin relieving pain and fever shortly after it is administered. However, the exact timing may vary slightly between individuals and depending on the specific condition being treated.

---

Q: Can Diclogesic Enfant cause sleeplessness or restlessness in children?

Official product information notes that some patients, including children, may experience agitation or insomnia (difficulty sleeping) as possible side effects. While these are not documented as the most common reactions, they are documented in association with the use of medicines like Diclogesic Enfant. If symptoms like agitation or insomnia are observed, consulting a healthcare provider is recommended, according to standard guidance.

---

Q: Does Diclogesic Enfant contain any ingredients that are known allergens?

Official regulatory documents list all excipients, or inactive ingredients, in Diclogesic Enfant, which may include substances that are potential allergens. For example, some formulations may contain sucrose and lactose, which is relevant for children with specific dietary restrictions or allergies. For children with known sensitivities, reviewing the full list of ingredients in the official product leaflet is advised.

How to Store and Dispose of Diclogesic Enfant?

Diclogesic Enfant (diclofenac) must be stored strictly according to its official labeling to maintain its stability. Store the medicine below 25^circC and keep it in the original package to protect it from moisture. It is mandatory to keep this and all medicines out of reach of children to prevent accidental ingestion.

Disposal Guidelines

To dispose of unused or expired Diclogesic Enfant, follow government guidelines to ensure environmental safety. The preferred method is to utilize a drug take-back program available in your community, such as those at pharmacies or police stations. If a take-back option is not available, the medicine should be mixed with an unappealing substance, placed into a sealed container or plastic bag, and then discarded in the household trash, with all personal information removed from the original packaging.